Efficacy of immunotherapy with combination of cryotherapy and topical imiquimod for treatment of Kaposi sarcoma. Issue 1 (19th December 2022)

• Record Type: Journal Article
• Authors: Gu, Lilly; Lin, Erica; Liu, Shuaitong; Yang, Ning; Kurtansky, Nicholas; Neumann, Neil M.; Stoll, Joseph; Lezcano, Cecilia; Pulitzer, Melissa; Noor, Sarah; Markova, Alina; Rossi, Anthony; Dickson, Mark A.; Deng, Liang
• Is Part Of: Journal of medical virology. Volume 95:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-19
• Subjects: Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28396
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Multiple treatment modalities for Kaposi sarcoma (KS) have been reported, including chemotherapy, radiation therapy, surgical excision, electrochemotherapy, and cryotherapy. Common topical treatments include timolol, imiquimod, and alitretinoin. We searched our institutional database for patients with ICD‐9 or 10 codes for KS seen by a dermatologist with experience in KS management from July 1, 2004 to January 1, 2022. We screened patient charts to include patients who received combination therapy of cryotherapy followed by topical imiquimod three times a week for 2 months ( n = 9). Patients were followed in the clinic every 3 months. Time to resolution was assessed by photographic evidence of resolution as determined by a dermatologist and corroborated with clinical documentation in patient charts. Median age (IQR) at KS diagnosis was 58 (27.5) years. All patients were male ( n = 9, 100%). Majority were white ( n = 7, 78%) and non‐Hispanic ( n = 8, 89%). Five (56%) had classic KS, one (11%) had HIV‐associated KS, and three (33%) were HIV‐negative men who have sex with men. Median time to resolution was 30.5 weeks, with a median of two treatments. In our study, 93% ( n = 42/45) of lesions and 89% ( n = 8/9) of patients experienced complete resolution during a median (range) duration of follow‐up of 58 (13–209) weeks. Side effects were limited to pain during cryotherapy, occasional blister formation after cryotherapy, and mild inflammation due to imiquimod. No infections were observed. Combination therapy of cryotherapy and topical imiquimod may be an efficacious and comparatively low‐risk treatment for limited, cutaneous KS.